• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Woori Bank Dec 12 Product Image

Woori Bank Dec 12

  • ID: 2359396
  • December 2012
  • Standard & Poors

Strong market position as Korea's second-largest bank Strong corporate banking business Good revenue diversification especially at the group level Relatively large exposure to construction and real estate/leasing businesses Potential pressure on asset quality from high household leverage Relatively weak core earnings The stable outlook on Woori Bank reflects our view that potential credit risks remain manageable and that the bank is likely to be able to maintain its current level of capitalization for the next 24 months. Standard & Poor's Ratings Services believes Woori will likely manage the potential rise in credit costs with current preprovisioning profit levels amid an increasingly challenging operating environment, characterized by potential pressure on the quality of household debt and ongoing pressure on the quality...

Companies mentioned in this report are:
- Woori Bank
- Woori Finance Holdings Co. Ltd.

Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown

- Woori Bank
- Woori Finance Holdings Co. Ltd.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.